The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
Go back to The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 251.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $251.65 | 52 Week High | $109.10 | |||
| Open | $251.65 | 52 Week Low | $31.38 | |||
| Day High | $251.65 | P/E | N/A | |||
| Day Low | $251.65 | EPS | $-1.45 | |||
| Volume | 1 | |||||
| Medicines Co (NASDAQ: MDCO) | Delayed: 84.90 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $84.90 | 52 Week High | $43.00 | |||
| Open | $3.15 | 52 Week Low | $27.50 | |||
| Day High | $84.90 | P/E | 339.60 | |||
| Day Low | $84.90 | EPS | $0.25 | |||
| Volume | 413,822 | |||||
